Nebenwirkungen · Humira
Humira 20 mg solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 19
HOS-111801 · Präparat HOS-093595
In controlled and open label adult and paediatric studies with Humira, serious infections (including fatal infections, which occurred rarely) have been reported, which include reports of tuberculosis (including miliary and extra-pulmonary locations) and invasive opportunistic infections (e.g. disseminated or extrapulmonary histoplasmosis, blastomycosis, coccidioidomycosis, pneumocystis, candidiasis, aspergillosis and listeriosis). Most of the cases of tuberculosis occurred within the first eight months after initiation of therapy and may reflect recrudescence of latent disease.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-08T11:41:00Z · SHA-256 0118f9ea31f7b28ac156bc8449293407c25bc43421a73fa92a30fe90db390eca · Passage 21901269144fb4c1de91c8b83be865f608c7be397859fd8f44dacd415b8f78d1 · Zeichen 18054–18638 im Abschnitt